Pulmonary aspergillosis: an alternative diagnosis to lung cancer after positive [18F]FDG positron emission tomography

Baxter, Caroline G.; Bishop, Paul; Low, Su Enn; Baiden-Amissah, Kweku; Denning, David W.

doi:10.1136/thx.2010.155515

Cited by 52 publications

(36 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This technique allows identification of metabolically active cells, such as inflammatory or malignant cells, which accumulate [ 18 F]FDG resulting in a distinct image on PET [36]. This technique was recently evaluated in patients with invasive fungal diseases and was demonstrated to be useful for the diagnosis and staging of this disease [36][37][38]. Of the 15 patients analysed here by [ 18 F]FDG-PET/CT, 13 were found to be positive (presence of hypermetabolic lesions), confirming the presence of an inflammatory process.…”

Section: Discussionmentioning

confidence: 97%

Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Likewise, several studies have proposed the usefulness of 18 F-FDG PET for evaluating infectious disease, although there are few data regarding pulmonary aspergillosis. 6,7 To the best of our knowledge, this is the first study to demonstrate and compare the features of IPA and NIPA using 18 F-FDG PET/CT, which is important because these 2 conditions require clearly different treatment plans.…”

mentioning

confidence: 97%

18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Findings Are Different Between Invasive and Noninvasive Pulmonary Aspergillosis

Kim

Yoo

et al. 2013

Journal of Computer Assisted Tomography

View full text Add to dashboard Cite

show abstract

“…Positron emission tomography (PET) doesn't appear to be useful, aspergillosis being one cause of a positive PET scan not attributable to malignancy (SoR D and QoE III) [57,60]. An isometabolic halo pattern and an isometabolic nodule pattern on 2-fluoro-2-deoxy-D-glucose PET/CT have been described in noninvasive pulmonary aspergillosis [58].…”

Section: Contribution Of Galactomannan Antigen To the Diagnosis Of Cpamentioning

confidence: 99%

Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management

Denning¹,

Cadranel²,

et al. 2015

View full text Add to dashboard Cite

Chronic pulmonary aspergillosis (CPA) is an uncommon and problematic pulmonary disease, complicating many other respiratory disorders, thought to affect ∼240 000 people in Europe. The most common form of CPA is chronic cavitary pulmonary aspergillosis (CCPA), which untreated may progress to chronic fibrosing pulmonary aspergillosis. Less common manifestations include: Aspergillus nodule and single aspergilloma. All these entities are found in non-immunocompromised patients with prior or current lung disease. Subacute invasive pulmonary aspergillosis (formerly called chronic necrotising pulmonary aspergillosis) is a more rapidly progressive infection (<3 months) usually found in moderately immunocompromised patients, which should be managed as invasive aspergillosis. Few clinical guidelines have been previously proposed for either diagnosis or management of CPA. A group of experts convened to develop clinical, radiological and microbiological guidelines. The diagnosis of CPA requires a combination of characteristics: one or more cavities with or without a fungal ball present or nodules on thoracic imaging, direct evidence of Aspergillus infection (microscopy or culture from biopsy) or an immunological response to Aspergillus spp. and exclusion of alternative diagnoses, all present for at least 3 months. Aspergillus antibody (precipitins) is elevated in over 90% of patients. Surgical excision of simple aspergilloma is recommended, if technically possible, and preferably via video-assisted thoracic surgery technique. Long-term oral antifungal therapy is recommended for CCPA to improve overall health status and respiratory symptoms, arrest haemoptysis and prevent progression. Careful monitoring of azole serum concentrations, drug interactions and possible toxicities is recommended. Haemoptysis may be controlled with tranexamic acid and bronchial artery embolisation, rarely surgical resection, and may be a sign of therapeutic failure and/or antifungal resistance. Patients with single Aspergillus nodules only need antifungal therapy if not fully resected, but if multiple they may benefit from antifungal treatment, and require careful follow-up. @ERSpublications ERS and ESCMID guideline for the management of chronic pulmonary aspergillosis released

show abstract

Pulmonary aspergillosis: an alternative diagnosis to lung cancer after positive [18F]FDG positron emission tomography

Cited by 52 publications

References 6 publications

Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series

Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series

18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Findings Are Different Between Invasive and Noninvasive Pulmonary Aspergillosis

Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management

Contact Info

Product

Resources

About